Sou Hu Cai Jing·2025-08-11 11:20Core Viewpoint - The company, Zhaoyan New Drug, has shown a significant increase in net profit despite a decline in revenue, indicating potential resilience in its business model within the pharmaceutical services industry [1][2]. Company Summary - Zhaoyan New Drug's closing price on August 11 was 31.22 yuan, reflecting a 3.38% increase, with a rolling PE ratio of 60.40 times and a total market capitalization of 23.399 billion yuan [1]. - The company operates primarily in non-clinical safety evaluation services for drugs, clinical research services, and sales of experimental animals and related products [1]. - For the first quarter of 2025, Zhaoyan New Drug reported revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit reached 41.1195 million yuan, a year-on-year increase of 115.11%, with a gross profit margin of 28.61% [1]. Industry Summary - The average PE ratio for the medical services industry is 48.03 times, with a median of 60.62 times, positioning Zhaoyan New Drug at the 29th rank within the industry [1][2]. - The company is among 17 institutions holding shares, with a total of 10.9687 million shares valued at 231 million yuan [1].